Difference between revisions of "Triclabendazole"
From Self-sufficiency
m (1 revision) |
|||
| Line 19: | Line 19: | ||
| routes_of_administration= ? | | routes_of_administration= ? | ||
}} | }} | ||
| − | '''Triclabendazole''' (commercial names: veterinary, liquid: '''Fasinex'''; human, tablets: '''Egaten'''; both manufactured by [[Novartis]]) is a member of the [[ | + | |
| + | '''Triclabendazole''' (commercial names: veterinary, liquid: '''Fasinex'''; human, tablets: '''Egaten'''; both manufactured by [[Novartis]]) is a member of the [[benzimidazole]] family of [[anthelmintics]]. The benzimidazole drugs share a common molecular structure, triclabendazole being the exception in having a chlorinated benzene ring but no [[carbamate]] group. | ||
Triclabendazole was initially only developed as an oral route drug and displays high efficacy against both immature and adult [[liver fluke]]. | Triclabendazole was initially only developed as an oral route drug and displays high efficacy against both immature and adult [[liver fluke]]. | ||
| − | It is generally accepted that benzimidazoles like triclabendazole bind to beta-tubulin and prevent the polymerisation of the [[microtubules]] of which they are part. | + | It is generally accepted that benzimidazoles like triclabendazole bind to [[beta-tubulin]] and prevent the polymerisation of the [[microtubules]] of which they are part. |
| + | |||
| + | Since latter nineties, triclabendazole came into generic situation as patents expired in many countries. Many products were developed then. Among them, Trivantel 15, a 15% triclabendazole suspension was launched by [[Agrovet Market Animal Health]] in early 2000s. In 2009, the first triclabendazole injectable solution (combined with ivermectin) was developed and launched also by [[Agrovet Market Animal Health]]. The product, Fasiject Plus, a triclabendazole 36% and [[ivermectin]] 0.6% solution, is designed to treat ''[[Fasciola hepatica]]'' (both immature and adult [[liver fluke]]), [[roundworms]] and ectoparasites as well. | ||
| + | |||
| + | == External links == | ||
| + | *[http://www.fasiject.com Fasiject Plus (a brand of triclabendazole + ivermectin) Website] | ||
| + | *[http://www.agrovetmarket.com Agrovet Market Animal Health Multilanguage Website] | ||
| + | |||
| − | |||
{{Anthelmintics}} | {{Anthelmintics}} | ||
| Line 33: | Line 40: | ||
[[Category:Organochlorides]] | [[Category:Organochlorides]] | ||
[[Category:Phenol ethers]] | [[Category:Phenol ethers]] | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
[[cs:Triklabendazol]] | [[cs:Triklabendazol]] | ||
Latest revision as of 13:52, 14 July 2010
 | This article does not cite any references or sources. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. (December 2009) |
| File:Triclabendazole.png | |
| Systematic (IUPAC) name | |
|---|---|
|
5-chloro-6-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzimidazole | |
| Clinical data | |
| Pregnancy category |
|
| Routes of administration | ? |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Metabolism | oxidation to the sulfone and sulfoxide parent compound |
| Biological half-life | 22 - 24 hs |
| Excretion | >95% in faeces, 2% in urine, and < 1% in milk |
| Identifiers | |
| CAS Number | 68786-66-3 |
| ATC code | P02BX04 (WHO) QP52AC01 |
| PubChem | CID 50248 |
| Chemical data | |
| Formula | C14H9Cl3N2OS |
| Molar mass | 359.658[[Script error: No such module "String".]] |
Triclabendazole (commercial names: veterinary, liquid: Fasinex; human, tablets: Egaten; both manufactured by Novartis) is a member of the benzimidazole family of anthelmintics. The benzimidazole drugs share a common molecular structure, triclabendazole being the exception in having a chlorinated benzene ring but no carbamate group.
Triclabendazole was initially only developed as an oral route drug and displays high efficacy against both immature and adult liver fluke.
It is generally accepted that benzimidazoles like triclabendazole bind to beta-tubulin and prevent the polymerisation of the microtubules of which they are part.
Since latter nineties, triclabendazole came into generic situation as patents expired in many countries. Many products were developed then. Among them, Trivantel 15, a 15% triclabendazole suspension was launched by Agrovet Market Animal Health in early 2000s. In 2009, the first triclabendazole injectable solution (combined with ivermectin) was developed and launched also by Agrovet Market Animal Health. The product, Fasiject Plus, a triclabendazole 36% and ivermectin 0.6% solution, is designed to treat Fasciola hepatica (both immature and adult liver fluke), roundworms and ectoparasites as well.
External links
- Fasiject Plus (a brand of triclabendazole + ivermectin) Website
- Agrovet Market Animal Health Multilanguage Website
Categories:
- Pages with script errors
- Articles lacking sources from December 2009
- Articles with invalid date parameter in template
- All articles lacking sources
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- 2Fix
- Benzimidazoles
- Anthelmintics
- World Health Organization essential medicines
- Organochlorides
- Phenol ethers
